Brief: Ocuphire Pharma Announces First Patient Enrolled In Late-stage Study Of Nyxol In Presbyopia
09/01/2023 13:08
Jan 9 (Reuters) - Ocuphire Pharma Inc OCUP.O :
* OCUPHIRE PHARMA ANNOUNCES FIRST PATIENT ENROLLED IN VEGA-2
PIVOTAL PHASE 3 TRIAL OF NYXOL® IN PRESBYOPIA
Source text for Eikon: ID:nGNX8jQxTV
Further company coverage: OCUP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Opus Genetics
See all newsUS RESEARCH ROUNDUP-Affiliated Managers Group, Goldman Sachs, Vaxcyte
Health Rounds: Experimental eye drops ease night vision problems for drivers
U.S. STOCKS ON THE MOVE-Apple, Omnicom, Jersey Mike's Subs
U.S. STOCKS ON THE MOVE-Airbnb, Lyft, Korn Ferry
Opus Genetics hits 5-year high on positive early- to mid-stage eye disease gene therapy data